4.1 Review

The ABCs of RVO: A review of retinal venous occlusion

Journal

CLINICAL AND EXPERIMENTAL OPTOMETRY
Volume 97, Issue 4, Pages 311-323

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1111/cxo.12120

Keywords

aflibercept; bevacizumab; macular oedema; pegaptanib; ranibizumab; retinal vein occlusion; sheathotomy; vascular endothelial growth factor; vitrectomy

Categories

Ask authors/readers for more resources

Retinal vein occlusions are important causes of loss of vision; indeed, they are the second most common retinal vascular disease, following diabetic retinopathy. For this reason alone, primary eye-care providers must be well versed in diagnosis and management. Risk factors, though not universally agreed upon, include but are not limited to advancing age, systemic hypertension, arteriolarsclerosis, diabetes, hyperlipidaemia, blood hyperviscosity, thrombophilia, ocular hypertension and glaucoma. Typically, visual loss is secondary to macular oedema and/or retinal ischaemia. Treatment modalities have included observation, systemic thrombolysis and haemodilution, radial optic neurotomy, chorioretinal anastomosis, vitrectomy, laser photocoagulation and intravitreal injection of anti-inflammatory and, most recently, anti-vascular endothelial growth factors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available